Accelerating the progress of biosimilars is key to lowering drug costs and improving patient access to potentially life-saving therapies.
Harold Carter, June 10, 22Read More
Patients getting access to expensive gene therapies is just one of the many challenges to bringing these sometimes life-saving drugs to market.
Mary Dorholt, PharmD, June 07, 22Read More
Biosimilars, gene and cell therapies, and cancer drugs are filling the specialty pipeline. Here are some insights for each category to help you stay informed. This topic was the focus of a breakout...
Harold Carter, April 20, 22Read More
As the number of approved gene and cellular therapies grows, you can start preparing your organization now by taking the right next steps.
Mary Dorholt, PharmD, October 28, 21Read More
Access, cost can be insurmountable hurdles unless the patient’s plan has the proper strategies in place
Jackie Huntebrinker, August 19, 21Read More
The first gene therapies have come to market. Hundreds more are in the drug pipeline.
Mary Dorholt, PharmD, July 08, 21Read More